Microbot Medical closes $2.66M registered direct offering of common stock and warrants at $2.20/share

Microbot Medical Inc.

Sold 975,000 shares at $2.20 and 234,500 pre-funded warrants at $2.1999, raising ~$2.66M gross.
Net proceeds to fund LIBERTY Robotic System development, commercialization, regulatory activities, and working capital.
Amended prior warrants: exercise price reduced to $2.20; 1,022,495 Series B warrants extended to Oct 25, 2027.
H.C. Wainwright served as placement agent; received 7% cash fee plus 60,475 warrants at $2.75 exercise price.

item 1.01 item 3.02 item 3.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Microbot Medical Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-05-16).

Action: entry
Agreement: underwriting
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2023-05-16

Exact text from the filing

On May 16, 2023 and in connection with the Offering, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Microbot Medical Inc. amended Warrant Amendment Agreement with the Investor.

Action: amendment
Counterparty: the Investor

Exact text from the filing

In connection with the Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Microbot Medical Inc. entered into Purchase Agreement with an institutional investor valued at approximately $2.66 million (effective 2023-05-23).

Action: entry
Agreement: equity purchase
Counterparty: an institutional investor
Value: approximately $2.66 million
Effective: 2023-05-23

Exact text from the filing

On May 23, 2023, Microbot Medical Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Offering”), (i) an aggregate of 975,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at an offering price of $2.20 per share and (ii) pre-funded warrants exercisable for up to 234,500 shares of Common Stock (the “Pre-Funded Warrants”) to the Investor at an offering price of $2.1999 per Pre-Funded Warrant, for aggregate gross proceeds from the Offering of approximately $2.66 million

View on SEC.gov

26 material agreements filed in the last 30 days. Browse all material agreements →

Microbot Medical Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-018932

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.